A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors
Clinical trial NCT04257110 · COMPLETED
Trial details
- NCT number
- NCT04257110
- Sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-28
- Primary completion
- 2024-08-31
- Enrollment
- 117
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.